394 results about "Lactobacillus fermentum" patented technology

The invention provides compound probiotics as well as a production process and an application thereof to a leavening agent. The compound probiotics are obtained as follows: strains with strong tolerance and excellent fermentation performance are combined and proportioned to prepare the dry powder of probiotics by virtue of strain activation and cultivation, fermentation, separation and vacuum low-temperature drying; and then the dry powder of probiotics is compounded and packaged to obtain the complex probiotics. A continuous vacuum low-temperature drying process is adopted, the period is shortened and the yield is improved; and the complex probiotics comprises lactobacillus plantarum, lactobacillus fermentum, lactobacillus casei and lactobacillus rhamnosus in a ratio of (2-8) to (1-6) to (1-4) to (1-3); during application, every ton of vegetable can be well fermented within 3-5 days by use of 0.2-1kg of the leavening agent at a fermenting temperature of 20-30 DEG C, wherein the fermentation time is shortened by 50% in comparison with that in the conventional method, the yield of the salted and preserved vegetable is over 75%. The multipurpose probiotics leavening agent prepared by the production process disclosed by the invention can be used for the vegetable fermenting industry and the feed fermenting industry, so that a realistic problem in agricultural production and a food processing process is solved; and meanwhile, the product quality and the production efficiency are improved.

The invention discloses a biomarker capable of detecting diseases. The biomarker at least comprises one of the following microbes or the combination of the following microbes: Akkermansia muciniphila, Bacteroides fragilis, Clostridium bolteae, Clostridium hathewayi, Clostridium sp.HGF2, Clostridium symbiosum, Eubacterium limosum, Lactobacillus fermentum, Lactobacillus salivarius, Ruminococcus torques, Streptococcus anginosus, Streptococcus infantis, Bacteroides stercoris, Bacteroides uniformis, Bilophila wadsworthia and Clostridiales sp.SS3/4. The invention further discloses an application of the biomarker for determining inflammatory bowel diseases. The invention also discloses a method, a system and a kit for detecting the biomarker in a tested object. According to the invention, through the research on intestinal flora, and through the high-throughput genome sequencing, the biomarker with high relativity with the inflammatory bowel diseases is screened out, and then the biomarker is utilized for accurately and efficiently detecting and diagnosing the inflammatory bowel diseases, and further used for monitoring the treatment effect for the disease.

Variant of the bacterium Lactobacillus fermentum and its use in treating gastrointestinal disorders, disorders of the mucosal surfaces or disturbances in the immune system or status of a subject.

The present invention provides an antiallergic agent containing, as an active ingredient, lactic acid bacteria selected from the group consisting of lactic acid bacteria of the species Lactobacillus acidophilus, Lactobacillus fermentum, and combinations thereof. The antiallergic agent is capable of improving allergic diathesis by reducing the IgE level, which is contributive to development of Type I allergy, and is easy to take and highly safe. The present invention also provides use of the antiallergic agent for reducing allergy, and a method for reducing allergy using the antiallergic agent.

The present invention relates to four kinds of lactobacilli, including Lactobacillus gasseri with preservation number of CGMCC No. 0840, Lactobacillus reuteri with preservation number of CGMCC No. 0841, Lactobacillus acidophilus with preservation number of CGMCC No. 0842 and Lactobacillus fermentum with preservation number of CGMCC No. 0843, separated from piglet intestinal tract and bred. The combination of the four kinds of lactobacilli is used in preparing the probiotics preparation for preventing and treating piglet ablactation diarrhoea and promoting growth, and the probiotic preparation is added into feed for ablactated piglet to prevent and treating diarrhoea and promote its growth.

The invention relates to a probiotic composition, and discloses a probiotic composition beneficial for a glycolipid metabolic function and a preparation and application of the composition. The probiotic composition comprises some of the following nine probiotics: bifidobacterium longum, bifidobacterium breve, lactobacillus gasseri, lactobacillus rhamnosus, lactobacillus salivarius, lactobacillus crispatus, lactobacillus plantarum, lactobacillus fermentum and lactobacillus casei. Different strains in the probiotic composition cooperate with each other, so that the probiotic composition has thefunction of adjusting glycolipid metabolism, and has certain effect on serum total cholesterol, triglycerides, insulin beta-cell functions and diabetes mellitus improvement.

The invention discloses a lactobacillus fermentum strain suitable for table vinegar brewing, wherein the classification name of the lactobacillus fermentum strain is Lactobacillus fermentum HS3-7, the Lactobacillus fermentum HS3-7 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation place is the Institute of Microbiology of Chinese Academy of Sciences located in 3, Courtyard 1, West Beichen Road, Chaoyang District, Beijing, the accession number is CGMCC NO.12226, and the preservation data is March 18, 2016. The invention further provides ready-to-use bacteria powder of the lactobacillus fermentum strain and applications of the bacteria powder. After the bacteria powder is used, the number of lactobacillus in table vinegar or other vinegar products can be obviously improved, the content of non-volatile acid is increased, and the flavor and quality of the product are improved.

The strain of micro-organism Lactobacillus fermentum ME-3 is a novel anti-microbial and anti-oxidative probiotic. It has a high anti-microbial effect on Escherichia coli, Shigella sonnei, Staphylococcus aureus, Salmonella typhimurium, and moderate activity against Helicobacter pylori strains. The strain of micro-organism possesses Mn-superoxide dismutase and both its lysates and intact cells have high anti-oxidative activity, increasing the glutathione red-ox ratio in blood sera and able to capture toxic hydroxyl radicals. The strain of micro-organism could be used as a probiotic for the production of functional food (yoghurt, cheese) and non-comestibles (tablets, capsules) for the prophylaxis of intestinal and uroinfections, both for the prevention and treatment of chronic diseases, caused by prolonged oxidative stress.

Six hop acids are common to hops and beer: alpha acid, beta acids, isoalpha acids, rho-isoalpha acids, tetrahydro-isoalpha acids, and hexahydro-isoalpha acids. The six hop acids were tested to determine which were the most effective in inhibiting the growth of bacteria common to fuel ethanol production. The bacteria used in the tests were Lactobacillus brevis and Lactobacillus fermentum. The minimum inhibitory concentrations (MIC) of the hop acids were determined using MRS-broth. Molasses mash and wheat mashes were used as the growth media for the fermentations. In all cases the hop acids controlled the growth of these two lactobacillus bacteria with tetrahydroisoalpha acid, hexahydroisoalpha acid, and isoalpha acid killing the most bacteria at the lowest MIC. Treating yeast propagators, steep tanks, and fermenters with a minimum inhibitory concentration of hop acids will stop bacteria growth, increase ethanol yields and avoid the need for antibiotics.

The invention relates to the field of microorganisms, and discloses lactobacillus fermentum capable of reducing blood uric acid. The strain is named 2644 strain, and is preserved at the China GeneralMicrobiological Culture Collection Center on 19th, November, 2018, and a microbial preservation number is CGMCC NO.16754; and the preservation authority address is NO.3 1# Courtyard, Beichen West Road, Chaoyang District, Beijing, and the microorganism is classified and named Lactobacillus fermentum. The strain can effectively reduce the content of the blood uric acid; and not only can intake of exogenous purines be reduced, but also discharge of internal uric acid from an intestinal tract can be promoted so that the blood uric acid level of a body can be more effectively controlled.

The present invention relates to a novel process for the selection of new probiotic strains which comprises the following steps: a) selecting for non-pathogenic strains which are capable of surviving in breast milk and/or amniotic fluid, and b) selecting for non-pathogenic strains which are able to be transferred to breast milk and/or amniotic fluid after oral intake in healthy individuals without colonizing other internal organs except mucousas. The invention also provides new Lactobacillus strains, which are: CECT5711 (Lactobacillus coryniformis), CECT5713 (Lactobacillus salivarius subsp. salivarius), CECT5714: (Lactobacillus gasseri, formerly L. acidophilus), CETC5715: (Lactobacillus gassen), and CECT5716: (Lactobacillus fermentum); and refers to their use for the prophylaxis or treatment against digestive, infective, neuro-degenerative and immune related diseases such as allergies or inflammatory diseases.

The invention relates to the field of microorganisms, and discloses lactobacillus fermentum with a weight reducing function and an application of the lactobacillus fermentum. The lactobacillus fermentum is named as WHH3906, is separated from butter collected in Tibet Autonomous Region in China, is preserved in China General Microbiological Culture Collection Center on March 13, 2020, has a preservation number of CGMCC NO.19472, and is classified and named as lactobacillus fermentum. The lactobacillus fermentum strain can effectively reduce serum leptin level to recover leptin sensitivity of anorganism, effectively prevent and treat obesity, relieve non-alcoholic fatty liver and relieve chronic inflammation. After being compounded with lactobacillus plantarum 1701, the lactobacillus fermentum can synergistically relieve chronic inflammation.

The invention discloses Lactobacillus fermentum zhao capable of regulating intestinal movement and preventing constipation and application thereof, wherein the preservation number of the Lactobacillus fermentum zhao is CCTCCM2013513. The strain has higher acid resistance, has a survival rate reaching 85.12% plus/minus 5.18% after staying in pH3.0 artificial gastric juice for 3 h, can grow slowly in cholate with the concentration of 1.0% and has a growth efficiency reaching 18.33% plus/minus 0.52% of that of cholate-free culture. The hydrophobicity of Lactobacillus fermentum zhao cells is up to 70.80% plus/minus 0.61%. The Lactobacillus fermentum zhao can grow normally in human intestinal tracts. In-vivo tests using mice show that the Lactobacillus fermentum zhao can reduce the weight reduction tendency of the mice, shorten the time of defecation of dark stool, improve the peristalsis of small intestines, increase MTL, Gas, ET, AchE, SP and VIP factors to different extents, reduce SS factors, increase food consumption and water consumption, reduce the tendency that stool amount, stool pieces and stool water content decline, play an effect similar to that of a constipation medicine and show a certain constipation prevention effect.